Replication Data for: Favorable effects, modes of use, and adverse reactions to cannabinoids in the management of autoimmune diseases: A scoping review.
<|begin_of_text|><|start_header_id|>system<|end_header_id|> You are a research archivist expert in dataset metadata. Answer the question truthfully.  <|eot_id|><|start_header_id|>user<|end_header_id|> Here is the Description of a dataset. Description:'Cannabinoids are coadjuvant drugs to treat chronic pain, fatigue, and spasticity symptoms in patients with autoimmune diseases[AImmDs]. We conducted a Scoping Review to provide an overview of the available evidence regarding the favorable effects, modes of use, and adverse drug reactions (ADRs) secondary to cannabinoids used as coadjuvant drugs for patients with AImmDs. Papers that estimated Cannabis, cannabinoids, or metabolites' effects on symptoms in AImmDs´ patients were retrieved, and data regarding specific cannabinoids, types [THC, CBD], drug presentation, administration route, outcomes measured, and adverse effects were described. 55 out of 71 papers were selected, 38 Randomized Clinical Trials[RCTs], and 17 Systematic Literature Reviews[SLRs], most focused in patients with Multiple Sclerosis (51/55;92.7%); Spasticity (29/55;52.' . Please return only a json list of at most 3 Keywords corresponding to the Description:.<|eot_id|><|start_header_id|>assistant<|end_header_id|> {"Answer" : ["autoimmune diseases","Cannabidiol","cannabinoids","Dronabinol","rheumatic diseases"]} <|eot_id|>
 Here is the Description of a dataset. Description:'Cannabinoids are coadjuvant drugs to treat chronic pain, fatigue, and spasticity symptoms in patients with autoimmune diseases[AImmDs]. We conducted a Scoping Review to provide an overview of the available evidence regarding the favorable effects, modes of use, and adverse drug reactions (ADRs) secondary to cannabinoids used as coadjuvant drugs for patients with AImmDs. Papers that estimated Cannabis, cannabinoids, or metabolites' effects on symptoms in AImmDs´ patients were retrieved, and data regarding specific cannabinoids, types [THC, CBD], drug presentation, administration route, outcomes measured, and adverse effects were described. 55 out of 71 papers were selected, 38 Randomized Clinical Trials[RCTs], and 17 Systematic Literature Reviews[SLRs], most focused in patients with Multiple Sclerosis (51/55;92.7%); Spasticity (29/55;52.' . Please return only a json list of at most 3 Keywords corresponding to the Description:.
Cannabinoids are coadjuvant drugs to treat chronic pain, fatigue, and spasticity symptoms in patients with autoimmune diseases[AImmDs]. We conducted a Scoping Review to provide an overview of the available evidence regarding the favorable effects, modes of use, and adverse drug reactions (ADRs) secondary to cannabinoids used as coadjuvant drugs for patients with AImmDs. Papers that estimated Cannabis, cannabinoids, or metabolites' effects on symptoms in AImmDs´ patients were retrieved, and data regarding specific cannabinoids, types [THC, CBD], drug presentation, administration route, outcomes measured, and adverse effects were described. 55 out of 71 papers were selected, 38 Randomized Clinical Trials[RCTs], and 17 Systematic Literature Reviews[SLRs], most focused in patients with Multiple Sclerosis (51/55;92.7%); Spasticity (29/55;52.
autoimmune diseases; Cannabidiol; cannabinoids; Dronabinol; rheumatic diseases